TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01525537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of sufentanil
Description: 10 microgram sufentanil were given when SPI above 50 for more then 20 sec

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil
Description: sufentanil was given at standard practise
Study: NCT03633682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headspace - Meditation and Mindfulness App
Description: Participants randomized to this arm will receive 1-month full access to the Headspace meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Headspace - Meditation and Mindfulness App
Description: Participants randomized to this arm will receive 1-month full access to the Headspace meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop, Breathe, & Think - Meditation and Mindfulness App
Description: Participants randomized to this arm will receive 1-month full access to the Stop, Breathe, \& Think meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stop, Breathe, & Think - Meditation and Mindfulness App
Description: Participants randomized to this arm will receive 1-month full access to the Stop, Breathe, \& Think meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
Study: NCT02279420

Intervention type: DEVICE
Group type: OTHER
Intervention: g-Cath EZ™ Suture Anchor Delivery Catheter
Description: This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
Study: NCT03876444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Methylprednisolone
Description: Intravenous Methylprednisolone will be used in the intervention group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Pednisolone
Description: Oral Prednisolone will be used in the Control Group
Study: NCT00089245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine I 131 MOAB 8H9
Description: Patients will be injected, intrathecally, with 2 mCi 131I-Omburtamab during week 1 of a 5 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine I 131 MOAB 8H9
Description: The dose used in this study is 50 mCi 131IOmburtamab, (averaging 5 mCi/mg Omburtamab at 50 mCi dose) which will be administered to each patient during week 2 of a 5 week cycle.
Study: NCT01938677

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Initial Gamma knife radiosurgery
Study: NCT01765088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: α-IFN
Description: 3mIU (3million) D1，3，5
Study: NCT00578812

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion (ACDF)
Description: Anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCM Cervical Disc
Description: PCM Cervical Disc replacement in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
Study: NCT00471068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travatan
Description: Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosopt
Description: treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Timolol Vehicle)
Description: Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
Study: NCT02681562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Study: NCT04188327

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: While the patient is in a supine position with slight neck extension and rotation to the contralateral side, in-plane ultrasound guided stellate ganglion block will be performed with injection of 7 ml injectate (6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg).~Each patient will receive:~* Acyclovir 800 mg orally every 5 times per day 7 days.~* Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Stellate ganglion block
Description: The patient will be positioned supine with slight neck extension and rotation to the contralateral side. Under US guidance, a sham stellate ganglion block will be performed with injection of a 1ml injectate of normal saline will be done while observing the dissection between the carotid artery and the longus colli muscle.~Each patient will receive:~* Acyclovir 800 mg orally every 5 times per day for 7 days.~* Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours
Study: NCT03954925

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomic anterior cruciate ligament with short hamstring graft technique
Description: ACL and short hamstring graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomic anterior cruciate ligament with a standard hamstring graft technique
Description: ACL with standard hamstring graft
Study: NCT00542425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA058 20 µg
Description: BA058 20 µg subcutaneous daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA058 40 µg
Description: BA058 40 µg subcutaneous daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA058 80 µg
Description: BA058 80 µg subcutaneous daily
Study: NCT01393704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
Study: NCT01797653

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CPAP therapy withdrawal
Description: CPAP (continuous positive airway pressure) with subtherapeutic pressure during two weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continue CPAP treatment
Description: Continue treatment with therapeutic continuous positive airway pressure device
Study: NCT02673437

Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study

Intervention type: OTHER
Intervention: This is a non-interventional study
Description: This is a non-interventional study
Study: NCT03629132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Platelet-rich plasma intrauterine injection

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: gel
Description: Self-crosslinking sodium hyaluronate gel intrauterine injection
Study: NCT03141476

Intervention type: DRUG
Group type: OTHER
Intervention: Cefuroxime 1,5g
Description: Patients with BMI of \<30kg/m\*m: 1,5 g Cefuroxime

Intervention type: DRUG
Group type: OTHER
Intervention: Cefuroxime 3g
Description: Patients with BMI of 30-50kg/m\*m: 3g Cefuroxime

Intervention type: DRUG
Group type: OTHER
Intervention: Cefuroxime 4,5g
Description: Patients with BMI of \>50kg/m\*m: 4,5 g Cefuroxime
Study: NCT03535844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wolfberry
Description: Consumption of cooked dehydrated wolfberry as part of a mixed meal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy diet
Description: Compliance to a healthy diet in accordance to recommendations by the Singapore Health Promotion Board.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy diet
Description: Compliance to a healthy diet in accordance to recommendations by the Singapore Health Promotion Board.
Study: NCT04847492

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional corticotomy
Description: A full-thickness mucoperiosteal flap will be elevated including the interdental papilla, and extended from the distal side of the second premolar on the right side to the same position on the left side without performing any vertical releasing incisions. Then, one vertical incision between the roots of upper anterior teeth and two vertical incisions in the site of first premolar extraction will be made by the piezosurgery knife.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flapless corticotomy
Description: Vertical soft-tissue incisions will be made on the buccal and palatal gingiva by using a blade N.15. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
Study: NCT02891759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alloderm RTU
Description: -Most commonly used acellular dermal matrices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cortiva 1mm Allograft Dermis
Description: -Tutoplast processed dermis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin or nipple-sparing mastectomy
Description: -Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin or nipple-sparing mastectomy
Description: -Standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast Q
Description: * 15 questions~* 10 questions in Part A asking how has the patient been feeling in past 24 hours, answers range from 0-10 with 0=none of the time and 10=all of the time~* Part B has 5 questions asking patient if she has had any of the following in the last 24 hours, answers ranging from 0-10 with 0=none of the time and 10=all of the time

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast Q
Description: * 15 questions~* 10 questions in Part A asking how has the patient been feeling in past 24 hours, answers range from 0-10 with 0=none of the time and 10=all of the time~* Part B has 5 questions asking patient if she has had any of the following in the last 24 hours, answers ranging from 0-10 with 0=none of the time and 10=all of the time

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: * To address the tissue expander~* Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: * To address the tissue expander~* Standard of care
Study: NCT02345629

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sharpness Sensory Testing
Description: Sharpness detection determined using 8, 10, 16, 20, 32, 64, and 128g weighted needle devices. Each stimulus applied for about 1 second in ascending order. Participants asked to rate each stimulus as producing the sensation of touch, pressure, sharp, or pain. The sharpness detection threshold defined as the mean force of the stimuli deemed ''sharp'' or ''painful'' from 3 trials separated by an average interval of 30 to 90 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sharpness Sensory Testing
Description: Sharpness detection determined using 8, 10, 16, 20, 32, 64, and 128g weighted needle devices. Each stimulus applied for about 1 second in ascending order. Participants asked to rate each stimulus as producing the sensation of touch, pressure, sharp, or pain. The sharpness detection threshold defined as the mean force of the stimuli deemed ''sharp'' or ''painful'' from 3 trials separated by an average interval of 30 to 90 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heat Pain Sensory Testing
Description: Thermal ramps will applied using a 3.6 x 3.6 cm Peltier thermode (Medoc Inc.) from a baseline temperature set at 32C. Skin heated at a rate of 0.30C/s, and participants asked to signal when the stimulus is perceived as first becoming warmer and then painfully hot.
Study: NCT00688974

Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass
Description: Laparoscopic Roux-en-Y gastric bypass

Intervention type: PROCEDURE
Intervention: Adjustable gastric band
Description: Laparoscopic adjustable gastric band
Study: NCT00590031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: pts will receive weekly cisplatin 30mg/m2 after hydration on weeks 8,9,11 and 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be given 65 mg/m2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: will be delivered with multiple (\>2) field techniques using mega-voltage radiation therapy. pts will receive 50.4 Gy and will be treated over a 6 week period.
Study: NCT03008889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Participants will start with taking 900mg of NAC once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will start with taking 900mg of the placebo once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events. The dosing for the placebo will increase in the same fashion as the active treatment.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63.
Study: NCT03131258

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Donor Nephrectomy
Description: 48 Donor Nephrectomy Patients
Study: NCT01191957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulphan plus Cyclophosphamide
Description: I.V. Bu (Busilvex), 12.8 mg/kg:~Day -9: 0.8 mg/kg/dose x 4 doses Day -8: 0.8 mg/kg/dose x 4 doses Day -7: 0.8 mg/kg/dose x 4 doses Day -6: 0.8 mg/kg/dose x 4 doses Day -5: Rest~Followed by:~Cyclophosphamide, 120 mg/kg iv:~Day -4: 60 mg/kg Day -3: 60 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulphan plus Fludarabine
Description: I.V. Bu (Busilvex), 12.8 mg/kg:~Day -6: 0.8 mg/kg/dose x 4 doses Day -5: 0.8 mg/kg/dose x 4 doses Day -4: 0.8 mg/kg/dose x 4 doses Day -3: 0.8 mg/kg/dose x 4 doses plus:~Fludarabine, 4 x 40 mg/m² iv:~Day -6: 40 mg/m² Day -5: 40 mg/m² Day -4: 40 mg/m² Day -3: 40 mg/m²
Study: NCT04525560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEG-ELS-S
Description: 2/3 dose of PEG-ELS was taken orally from the evening on the day before colonoscopy, and the remaining 1/3 dose of PEG-ELS was orally administered in the morning of the next day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEG-ELS-L
Description: PEG-ELS is given orally on the day before colonoscopy, which is divided into 10-12 portions and taken one portion every hour. If half of the total amount is not completed at afternoon ward round the day before colonoscopy, nasogastric feeding is recommended.
Study: NCT03873233

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aisys Carestation ventilator and normal endotracheal tube
Description: Fraction of Inspired Oxygen (FIO2) 0.3 End Expiratory Pressure (EEP) at +5 cm H2O Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 Tidal Volume: 6 mL/kg Zero inspiratory pause Respiratory frequency will be adapted to produce an End-Tidal CO2 35-40 mmHg
Study: NCT02966665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximum Exercise Tests
Description: Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximum Exercise Tests
Description: Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximum Exercise Tests
Description: Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximum Exercise Tests
Description: Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximum Exercise Tests
Description: Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.
Study: NCT00976261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1614235
Description: Glucose lowering in Type 2 Diabetes Mellitus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Glucose lowering in Type 2 Diabetes Mellitus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator
Study: NCT03278925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defined Green Tea Catechin Extract
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo ultrasound
Study: NCT04144062

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM crowns
Description: CAD/CAM crowns

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM crowns
Description: CAD/CAM crowns
Study: NCT00985140

Intervention type: RADIATION
Intervention: Total Skin Electron Beam Therapy (TSEBT)
Description: The purpose of the study is to examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray (TSEBT 12 Gray) in patients who have mycosis fungoides (MF) staged as IB to IIIB.
Study: NCT02557815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive 10Hz right DLPFC stimulation using Magstim TMS apparatus

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive 10Hz right DLPFC stimulation using Magstim TMS apparatus